Lecope-M Kid Tablet DT is a pediatric formulation combining Levocetirizine 2.5 mg and Montelukast 4 mg, designed for the management of allergic conditions in children. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 histamine receptors, thereby alleviating symptoms such as sneezing, rhinorrhea, and itching associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, reducing inflammation and bronchoconstriction commonly observed in asthma and allergic rhinitis. The dual-action mechanism provides comprehensive relief from allergic symptoms by targeting both histamine-mediated and leukotriene-mediated pathways. Lecope-M Kid Tablet DT is formulated as a dispersible tablet, facilitating easy administration and rapid onset of action in pediatric patients who may have difficulty swallowing conventional tablets. It is indicated for children aged 2 years and above for the treatment of allergic rhinitis, chronic urticaria, and as an adjunct therapy in mild to moderate asthma. The combination therapy improves symptom control, enhances quality of life, and reduces the frequency of asthma exacerbations. Lecope-M Kid Tablet DT should be used under medical supervision, with dosage adjustments based on clinical response and tolerability.